Unknown

Dataset Information

Transcriptomic analysis of EGFR co-expression and activation in glioblastoma reveals associations with its ligands.


ABSTRACT:

Background

Approximately half of the isocitrate dehydrogenase (IDH)-wildtype glioblastomas (GBMs) exhibit EGFR amplification. Additionally, genomic changes that occur in the extracellular domain of EGFR can lead to ligand-hypersensitivity (R108K/A289V/G598V) or ligand-independence (EGFRvIII). Unlike in lung adenocarcinoma (LUAD), clinical trials with epidermal growth factor receptor (EGFR) inhibitors showed no survival benefit for GBM and it remains unclear why. We aimed to elucidate differences in molecular mechanisms of EGFR activation and regulation between GBM and LUAD.

Methods

We used RNA-sequencing (RNA-seq) data to find EGFR co-regulated genes and pathways in GBM and compare EGFR signaling patterns between GBM and LUAD. Cellul

SUBMITTER: Ghisai SA 

PROVIDER: S-EPMC11829203 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature